Globes [online] is reporting that NiliMEDIX, a manufacturer of disposable insulin pumps from Israel, has filed a 510k fast-track application for FDA approval to market its devices in the US.
Here’s how the company explains the technology:
NiliMEDIX develops innovative durable (to be used for several years) and disposable (replaced every 2-3 days) insulin pumps for helping diabetics manage their diabetes.
Insulin pumps deliver insulin the way a healthy pancreas does allowing freedom in daily activities and improving the quality of life of their users.
Moreover, the pumps usually decrease the needed daily amount of insulin by reducing the insulin resistance of the body cells and reduce the number of hypoglycemia and hyperglycemia incidences.
In production of the its pumps, NiliMEDIX is integrating advanced microelectronic technologies. The developed pumps are passive based on Discrete Pressure Compensation (DPC) technology using sensitive pressure and temperature sensors monitored by microprocessors and are implementing MEMS and microinjection technologies that assure high repeatability, safety, accuracy, small dimensions and low production costs.
NiliMEDIX insulin pumps have several unique features over presently available pumps (under development). Among them:
Less malfunctions, as it has no moving parts such as motor, reduction gear etc. Lowest energy consumption (AAA battery). Low production cost. Delivers true and even doses at all times. Unique ability to sensing air bubbles. Reliable(at real time) occlusion sensing Infusion set disconnection warning. Leakage alarm. Air bubbles are NOT counted as a given dose of insulin Does not accidentally oversupply insulin.